Diabetes is one of the most pressing global health challenges of the 21st century, affecting over 530 million adults worldwide. Insulin, a cornerstone of diabetes management for type 1 and many type 2 diabetes patients, remains a life-sustaining therapy. However, the high cost of brand-name insulins has created significant barriers to access, particularly in low- and middle-income countries and even among underinsured populations in high-income nations. Recent advances in biosimilar insulins are poised to reshape the treatment landscape by offering more affordable, high-quality alternatives that can deliver the same clinical outcomes as their reference biologics. As regulatory frameworks mature and manufacturing technologies improve, biosimilar insulins represent a critical tool in the global effort to achieve cost-effective diabetes care.

Understanding Biosimilar Insulins

Biosimilar insulins are biologic products that are highly similar to an already approved reference insulin biologic—often referred to as the originator or innovator product. Unlike small-molecule generic drugs, which are exact chemical copies, biologics are large, complex proteins produced in living systems. This complexity makes it impossible to create an identical copy. Instead, biosimilars are rigorously compared to the reference product through analytical, non-clinical, and clinical studies to demonstrate that any minor differences are not clinically meaningful in terms of safety, purity, and potency.

The key difference between a biosimilar and a generic is the degree of similarity required. A generic drug must be bioequivalent to the brand-name drug with identical active ingredient. For biosimilars, the active substance is similar but not identical due to the nature of biologic manufacturing. Regulatory agencies—such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—have defined strict approval pathways to ensure that biosimilar insulins meet the same high standards of efficacy and safety as the reference product. Common examples of reference insulins include insulin glargine (Lantus), insulin lispro (Humalog), and insulin aspart (NovoLog). Biosimilar versions of these insulins are now available in many markets under brand names such as Basaglar, Admelog, and Saroglitazar (though the latter is an insulin sensitizer, not a biosimilar per se).

Biosimilar insulins are not interchangeable with other biologic insulins unless specifically designated as interchangeable by a regulatory authority. Interchangeability status allows a pharmacist to substitute a biosimilar for the reference product without prescriber approval, similar to generic drug substitution. To date, only a few biosimilar insulins have received interchangeability designations, but this is an area of active regulatory evolution.

Recent Advances in Biosimilar Insulin Development

The past decade has witnessed remarkable progress in biosimilar insulin development, driven by both patent expirations and increasing demand for affordable therapies. Advances in manufacturing technologies—such as recombinant DNA techniques, improved purification processes, and more robust quality control—have enabled the production of biosimilars that are highly consistent with the reference product. Several notable biosimilar insulins have entered the market or are in late-stage clinical trials:

  • Biosimilar Insulin Glargine: The most widely adopted biosimilar insulin to date. Products like Basaglar (approved in the US and EU) and Lantus biosimilars in emerging markets have demonstrated equivalent glycemic control, safety, and immunogenicity profiles. Recent studies confirm that switching from reference insulin glargine to the biosimilar does not compromise outcomes.
  • Biosimilar Insulin Lispro: Humalog biosimilars such as Admelog (US/EU) have been available since 2020. They offer the same rapid-acting profile and are often priced significantly lower, helping patients manage postprandial glucose spikes affordably.
  • Ultra-Long-Acting Biosimilars: Researchers are developing biosimilar versions of next-generation insulins like insulin degludec (Tresiba). Although degludec patents still apply in some regions, biosimilar development is underway in countries where patents have expired, promising once-daily or twice-weekly dosing options at lower cost.
  • Improved Delivery Devices: Many biosimilar insulins are now available in pre-filled pens with fine needles and dose memory functions, enhancing patient adherence and reducing injection pain. Some devices incorporate smart technology that connects to mobile apps for dose tracking.

These developments are not limited to large pharmaceutical companies. Biotech firms in countries such as India, China, and Brazil are actively manufacturing biosimilar insulins for local and global markets. The World Health Organization’s (WHO) prequalification program has started approving biosimilar insulins, facilitating their distribution in developing nations and UN procurement programs.

Benefits: Cost-Effectiveness and Expanded Access

The primary driver behind biosimilar insulin adoption is cost reduction. Biosimilars are typically priced 20–40% lower than the reference product, with some studies reporting even greater discounts in competitive markets. For a patient requiring multiple vials or pens per month, the savings can amount to hundreds or even thousands of dollars annually. This financial relief directly improves medication adherence, as patients are less likely to ration insulin or skip doses due to cost.

Moreover, biosimilar insulins reduce overall healthcare system costs. A 2021 study in the Journal of Managed Care & Specialty Pharmacy estimated that if biosimilar insulins captured 50% of the US market, total savings could exceed $5 billion over five years. These savings free up resources for other diabetes-related expenses, such as glucose monitoring supplies, diabetes education, and complications management.

Access implications are particularly profound in low- and middle-income countries (LMICs), where insulin affordability remains a major barrier. According to the International Diabetes Federation (IDF), more than half of people with diabetes living in LMICs lack access to insulin and essential diabetes care. Biosimilar insulins, especially those produced locally and prequalified by WHO, can help close this gap. For instance, the Indian pharmaceutical company Biocon’s biosimilar insulin glargine, Basalog, is widely used across Asia and Africa at a fraction of the cost of Lantus.

Increased competition also stimulates innovation among originator manufacturers, who respond by lowering prices, improving delivery systems, or developing novel insulins. This dynamic benefits all stakeholders—patients, providers, payers, and policymakers—by creating a more sustainable diabetes care ecosystem.

Regulatory Framework and Approval Pathways

Biosimilar insulins are approved through stringent regulatory pathways that balance patient safety with market access. Although specific requirements vary by jurisdiction, the core principles are consistent: demonstrate similarity in structure, function, pharmacokinetics, pharmacodynamics, and lack of clinically meaningful differences in efficacy and safety.

United States (FDA)

The FDA approves biosimilar insulins under the Biologics Price Competition and Innovation Act (BPCIA). Manufacturers must submit a Biologics License Application (BLA) with extensive analytical data, animal studies, and at least one clinical study—often a phase 3 trial in patients with type 1 or type 2 diabetes. Insulin glargine biosimilar Basaglar was the first insulin biosimilar approved in the US in 2015, followed by insulin lispro biosimilar Admelog in 2017. The FDA also designates interchangeability based on additional switching studies; to date, Basaglar is not designated as interchangeable, but other insulins may achieve that status in the future.

European Union (EMA)

The EMA has been at the forefront of biosimilar regulation, approving the first biosimilar insulin (insulin glargine biosimilar) in 2014. The EMA requires a comprehensive comparability exercise, including in vitro assays, pharmacokinetic/pharmacodynamic studies, and clinical safety and efficacy trials. Notably, the EMA allows extrapolation of indications from the reference product to the biosimilar if scientifically justified, which reduces redundant trials. As a result, the EU market now has multiple biosimilar insulins for glargine, lispro, and aspart, giving prescribers a range of affordable options.

WHO Prequalification

To facilitate access in resource-limited settings, the WHO began prequalifying biosimilar insulins in 2021. This program evaluates manufacturing quality, safety, and efficacy, and allows UN agencies and national procurement bodies to purchase approved biosimilars with confidence. The first WHO-prequalified biosimilar insulin was a glargine product from Biocon. This initiative has been lauded as a major step toward universal health coverage for diabetes.

Despite these advances, regulatory harmonization remains a challenge. Some countries lack clear biosimilar guidelines, leading to market confusion and delayed uptake. International collaborations, such as the International Generic and Biosimilar Medicines Association (IGBA), work toward standardizing requirements to accelerate global access.

Challenges to Widespread Adoption

Despite their proven benefits, biosimilar insulins face several hurdles that slow adoption in both mature and emerging markets. Addressing these barriers is essential to fully realize the potential cost savings and access improvements.

Physician and Patient Awareness

Many healthcare providers and patients remain unfamiliar with biosimilars or harbor misconceptions about their safety and efficacy. Surveys indicate that a significant portion of physicians are hesitant to prescribe a biosimilar insulin because they believe it is inferior to the originator. Educational initiatives targeting prescribers—such as continuing medical education (CME) programs, clinical guidelines endorsements, and real-world evidence dissemination—are critical to building trust. Patient education is equally important; individuals with diabetes need clear, reassuring information about what biosimilars are and why switching is safe.

Interchangeability and Substitution Policies

Lack of interchangeability status for many biosimilar insulins complicates pharmacy-level substitution. In the US, only a few biosimilar insulins have been granted interchangeable designation by the FDA, meaning that a pharmacist cannot automatically substitute without prescriber approval. Even in regions with supportive policies, prescribing inertia—where clinicians continue to use the originator out of habit or perceived lower risk—slows uptake. Policy interventions such as automatic substitution laws, formulary inclusion, and favorable reimbursement rates can help overcome these barriers.

Manufacturing and Supply Chain Issues

Producing biologic insulins is technically demanding and requires significant capital investment. Small biotech firms may struggle to achieve the scale needed to compete with established manufacturers. Additionally, supply chain disruptions—exacerbated by geopolitical tensions or pandemics—can affect biosimilar availability. Governments can mitigate this by supporting domestic biosimilar production and stockpiling essential insulins.

Patent thickets, litigation, and data exclusivity periods can delay biosimilar market entry even after reference product patents expire. In some countries, originator companies employ legal strategies to extend monopolies, such as filing secondary patents on delivery devices or manufacturing processes. Reforms to strengthen biosimilar competition, such as transparent patent listings and robust biosimilar approval pathways, are needed to reduce time to market.

Future Outlook and Ongoing Research

The biosimilar insulin landscape is dynamic, with numerous developments on the horizon that promise to further improve affordability and convenience. Some emerging areas include:

Next-Generation Biosimilars and Novel Formulations

Beyond copying existing products, biosimilar developers are exploring improved formulations that offer longer duration of action, faster onset, or greater stability at room temperature. For example, researchers are working on biosimilar versions of ultra-long-acting insulins (e.g., insulin icodec, which is not yet off-patent) as well as smart insulins that respond to blood glucose levels. While these are still in early stages, the success of biosimilars will fund further innovation.

Oral and Inhalable Biosimilar Insulins

The holy grail of insulin delivery is non-invasive administration. Several companies are developing biosimilar versions of oral insulin (e.g., using encapsulation technologies) and inhalable insulin (like Afrezza). If these products meet safety and efficacy standards and reach cost parity, they could transform diabetes management, especially in resource-limited settings where injection access and disposal are problematic.

Real-World Evidence and Post-Market Surveillance

As biosimilar insulins become more widely used, collecting real-world evidence on outcomes, adherence, and adverse events is crucial for continued confidence. Large observational studies in countries like the UK, where biosimilar glargine has been heavily adopted, show no increased risk of hypoglycemia or other complications. Such data will support regulatory decisions on interchangeability and encourage broader prescribing. Additionally, digital health tools—smartphone apps, connected pens, and continuous glucose monitors—can track real-time outcomes and provide feedback to patients and physicians.

Policy and Partnership Initiatives

Global health organizations are increasingly promoting biosimilar insulins through partnerships and funding mechanisms. The WHO’s Global Diabetes Compact aims to ensure that all people with diabetes have access to affordable insulin by 2030, with biosimilars as a key pillar. Similarly, programs like the Access to Insulin Project (ATIP) help countries negotiate lower prices and improve supply chains. As these initiatives gain momentum, the adoption of biosimilar insulins will likely accelerate.

Conclusion

Biosimilar insulins represent a paradigm shift in diabetes care, offering a cost-effective, safe, and efficacious alternative to expensive originator biologics. Recent advances in manufacturing, regulatory approvals, and market access have enabled millions of patients worldwide to benefit from lower insulin prices and improved adherence. However, realizing the full potential of biosimilar insulins requires sustained effort from all stakeholders—clinicians must embrace evidence-based prescribing, regulators must streamline approval pathways and promote interchangeability, and policymakers must create incentives for competition and production. With continued research, education, and collaborative action, biosimilar insulins can substantially reduce the global burden of diabetes and help achieve the vision of universal, affordable insulin access for all who need it.